Clinical Trial Update: Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update on using Umbilical Cord Mesenchymal Stem Cells (UC-MSC) and conditioned media (CM) to slow vision loss in Retinitis Pigmentosa; the study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinitis Pigmentosa

Drugs mentioned

• Mesenchymal stem cell conditioned media (CM) (conditioned media)
• UC-MSC (Umbilical Cord Mesenchymal Stem Cells) (umbilical cord mesenchymal stem cells)

Snippet

Sponsor: PT. Prodia Stem Cell Indonesia | Conditions: Retinitis Pigmentosa | Phase 2, Phase 3 | Status: NOT_YET_RECRUITING